This trial has been terminated.

Condition duchenne muscular dystrophy
Treatments pro045, 0.15 mg/kg/week, pro045, 1.0 mg/kg/week, pro045, 3.0 mg/kg/week, pro045, 6.0 mg/kg/week, pro045, 9.0 mg/kg/week, pro045, selected dose
Phase phase 1/phase 2
Sponsor BioMarin Pharmaceutical
Start date January 2013
End date July 2017
Trial size 15 participants
Trial identifier NCT01826474, PRO045-CLIN-01


The purpose of the study is to see whether PRO045 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA for the dystrophin protein.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
0.15 mg/kg until dose-titration
pro045, 0.15 mg/kg/week
Subcutaneous injection
1.0 mg/kg until dose-titration
pro045, 1.0 mg/kg/week
Subcutaneous injection
3.0 mg/kg until dose-titration
pro045, 3.0 mg/kg/week
Subcutaneous injection
6.0 mg/kg until dose-titration
pro045, 6.0 mg/kg/week
Subcutaneous injection
9.0 mg/kg until move to 48 week treatment phase
pro045, 9.0 mg/kg/week
Subcutaneous injection
48 week treatment phase
pro045, selected dose
Subcutaneous injection

Primary Outcomes

Change from baseline in 6 minute walk test
time frame: after 48 weeks of treatment phase

Secondary Outcomes

Muscle function
time frame: after 48 weeks of treatment phase
Muscle strength
time frame: after 48 weeks treatment phase
Performance of upper limb
time frame: after 48 weeks of treatment phase
Functional outcomes questionnaire
time frame: after 48 weeks of treatment
time frame: after 48 weeks of treatment phase

Eligibility Criteria

Male participants from 5 years up to 18 years old.

Inclusion Criteria: 1. Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO045 confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition Amplification/Internal Primer) or HRMCA (High-Resolution Melting Curve Analysis), and correctable by PRO045-induced DMD exon 45 skipping in cultured skin-derived myo-converted fibroblasts. 2. Ambulant boys aged at least 5 years on the day of first dosing able to walk for at least 230 meters in the 6 minute walking distance (6MWD) test at first screening visit and also at the baseline visit. In addition, 2 of the 3 pre-treatment 6MWD tests (screen 1, screen 2, baseline) must be within +/-30 metres of each other prior to first PRO045 administration. 3. Adequate quality for biopsy (confirmed with MRI) of the lateral head of the gastrocnemius muscle. An alternative muscle may be considered for biopsy but only following discussion between the Principal Investigator and the Prosensa Medical Monitor. 4. Life expectancy of at least 3 years after inclusion in the study. 5. Glucocorticosteroid use which is stable for at least 3 months prior to first PRO045 administration. Subjects must have been receiving glucocorticosteroids for at least 6 months prior to the first PRO045 administration. 6. Willing and able to adhere to the study visit schedule and other protocol requirements. 7. Written informed consent signed (by parent(s)/legal guardian and/or the subject, according to the local regulations). 8. In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category. Exclusion Criteria: 1. Known presence of dystrophin in ≥5% of fibres in a pre-study diagnostic muscle biopsy (i.e. historic muscle biopsy taken prior to written informed consent for this study). 2. Current or history of liver disease or impairment. 3. Current or history of renal disease or impairment. 4. At least two aPTT above ULN within the last month. 5. Screening platelet count below the lower limit of normal (LLN). 6. Acute illness within 4 weeks prior to first dose of PRO045 which may interfere with the study assessments. 7. Severe mental retardation or behavioural problems which in the opinion of the investigator prohibits participation in this study. 8. Severe cardiomyopathy which in the opinion of the investigator prohibits participation in this study. If a subject has a left ventricular ejection fraction <45% at screening, the investigator should discuss inclusion of the subject with the Medical Monitor. 9. Expected need for daytime mechanical ventilation within the next year. 10. Use of anticoagulants, antithrombotics or antiplatelet agents. 11. Use of idebenone or other forms of coenzyme Q10 within 1 month prior to the start of the screening for the study. 12. Use of nutritional or herbal supplements which, in the opinion of the investigator, may influence muscle performance, within 1 month of the study. 13. Use of any other investigational product or participation in another trial with an investigational product, within 6 months prior to the start of the screening for the study.

Additional Information

Official title A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy
Principal investigator T. Voit, MD PhD
Description A phase IIb, open-label, multiple-dose study. The study consists of two phases; a dose escalation phase (with subsequent dose-titration) and a 48-week treatment phase.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by BioMarin Pharmaceutical.